FEops closes a €1.3m series A financing round to commercialise its TAVIguide™ service
20 January 2015 | By B3C newswire
TAVIguide™ supports transcatheter aortic valve implantation (TAVI)...
List view / Grid view
News
Celgene’s Otezla® (Apremilast) receives European Marketing Authorisation
19 January 2015 | By Celgene
An oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements...
Applications invited for clinical pharmacy research grant
19 January 2015 | By The UK Clinical Pharmacy Association and Pharmacy Research UK
The UK Clinical Pharmacy Association (UKCPA) and Pharmacy Research UK are continuing their partnership in 2015 to offer a research fund of up to £50,000 to support pharmacy practitioners to take forward their research within clinical pharmacy...
Switzerland first country to launch Xultophy® (IDegLira)
19 January 2015 | By Novo Nordisk
Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes...
Alliance Pharma plc pre-close trading update
19 January 2015 | By Alliance Pharma plc
Alliance Pharma plc, the speciality pharmaceutical company, announces its pre-close trading update ahead of its preliminary results for the year ended 31 December 2014...
Roche opens new Learning Center in Kaiseraugst
19 January 2015 | By Roche
Today Roche opened its new Learning Center in Kaiseraugst. Besides offering a superlative infrastructure for trainees, the Learning Center contains a state-of-the-art school laboratory, which in this form is unparalleled in Switzerland...
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
19 January 2015 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...
PHE and NHS England launch joint £11.5M strategy to wipe out TB in the UK
19 January 2015 | By Public Health England press office
10-point action plan aims to eradicate TB across England...
Two volunteers with potential exposure to Ebola transported to UK for precautionary monitoring
19 January 2015 | By Public Health England Press Office
All appropriate public health actions taken to support individuals and protect public health...
Shire completes ‘robust’ deal in $5.2 billion NPS Pharmaceuticals acquisition, says GlobalData Analyst
16 January 2015 | By GlobalData
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData...
BGMA and MHRA come together for quality forum
The British Generic Manufacturers Association will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Tuesday, February 24th...
Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
16 January 2015 | By Roche
Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France...
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
BIOTRONIK announces first enrollments in new study evaluating reduction of Thromboembolic events via GoldTip ablation
15 January 2015 | By BIOTRONIK
Trial to demonstrate efficacy of AlCath Flux eXtra gold ablation catheter in Reducing the incidence of harmful Thromboemboli...
Denmark’s pharmaceutical market value to decline to $3 billion by 2020, says GlobalData
14 January 2015 | By GlobalData
Denmark’s pharmaceutical market will decline in value from $3.5 billion in 2013 to $3 billion by 2020, with price-cap agreements and high tax rates on pharmaceutical products two of the largest barriers to growth, according to research and consulting firm GlobalData...
